High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Valuation Metrics
The current forward P/E ratio for Scinai Immunotherapeutics Ltd (SCNI.O) is 0.00, compared to its 5-year average forward P/E of -13.14. For a more detailed relative valuation and DCF analysis to assess Scinai Immunotherapeutics Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-13.14
Current PE
0.00
Overvalued PE
53.38
Undervalued PE
-79.67
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
SCNI News & Events
Events Timeline
(ET)
2025-07-29
07:26:53
Scinai Immunotherapeutics' PC111 featured in peer-reviewed publication
2025-03-05 (ET)
2025-03-05
07:31:58
Scinai Immunotherapeutics announces $10M standby equity purchase agreement
2025-03-04 (ET)
2025-03-04
17:28:27
Scinai Immunotherapeutics files to sell 3.02M ADS for holders
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/newsfilter.png)
Preview
9.0
07-29NewsfilterScinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/eb9dc38257214e4a099e2382afd1c408153a4964b6e3cb923986cd8b8ae570e8.png)
Preview
9.5
07-29BenzingaWhy Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/b9488a725df2fb6a81e8897417477a103388445980e6f024a52b20e48df41b21.png)
Preview
7.5
06-26PRnewswireScinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"
Sign Up For More News
People Also Watch
FAQ
What is Scinai Immunotherapeutics Ltd (SCNI) stock price today?
What is Scinai Immunotherapeutics Ltd (SCNI)'s business?
What is the price predicton of SCNI Stock?
What is Scinai Immunotherapeutics Ltd (SCNI)'s revenue for the last quarter?
What is Scinai Immunotherapeutics Ltd (SCNI)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Scinai Immunotherapeutics Ltd (SCNI)'s fundamentals?
How many employees does Scinai Immunotherapeutics Ltd (SCNI). have?